Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00173290
First received: September 12, 2005
Last updated: June 2, 2008
Last verified: June 2005
  Purpose

In this study proposal, the investigators will extend their previous studies and examine the kinetic cytotoxic activity with concordant expression of inhibitory natural killer (NK) receptors (iNKR) on activated T cells. The inhibitory role of cytokines will be defined by utilizing the investigators' previously established models of mixed lymphocytes and tumor cells coculture to analyze the expression and activity of cytokines involved in the regulation of iNKRs on cancer-encountered T cells.


Condition
Cervical Cancer
Breast Cancer
Endometrial Cancer
Cancer

Study Type: Observational

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 200
Study Start Date: July 2004
Estimated Study Completion Date: December 2006
Detailed Description:

In our extended studies, we have directly examined the expressions of various inhibitory natural killer cell Receptors (iNKRs) on Tumor-infiltrating lymphocytes (TILs) derived from human Cervical cancer (CC) by triple-color flow cytometry with combination of different surface markers. We found up-regulated expression of certain iNKRs (CD94/NKG2A) in TILs and in mixed lymphocyte-cancer cell cocultures. In our previous studies, we demonstrated that certain cytokines, including IL-10, TGF-beta (Sheu et al, Journal of Immunology, 2001, 167:2972-2978), and IL-15 (Sheu et al, Cancer Research, 2005, 65:2921-2929) can be expressed by CC cells. We further demonstrated that activated T cells bear iNKRs which inhibit cytotoxic activity. iNKRs are proposed to restrain the T cell receptor (TCR)-mediated cytolysis. We found that CC cells had altered HLA-A, -B, and -C molecules in a cancer microenvironment. The acquisition of both NK-like activity and expression of iNKRs by these T cells is parallel to prevent damage to normal host cells. However, there is also limited knowledge about the regulatory role of iNKR expression in T cell cytotoxicity.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Cancer patients
  • Healthy volunteers

Exclusion Criteria:

  • Immunosuppression
  • HIV carrier
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00173290

Contacts
Contact: Bor-Ching Sheu, MD, PhD 886-2-2312-3456 ext 5559 bcsheu@ha.mc.ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Bor-Ching Sheu, MD, PhD    886-2-2312-3456 ext 5559    bcsheu@ha.mc.ntu.edu.tw   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Bor-Ching Sheu, MD, PhD Department of Obstetrics and Gynecology, National Taiwan University Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00173290     History of Changes
Other Study ID Numbers: 9461700613, NTUH 94-S045, NTUH 95-0399, NTUCM-9406, NSC93-2314-B002-065, NSC93-2314-B002-164
Study First Received: September 12, 2005
Last Updated: June 2, 2008
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Cervical cancer
Breast cancer
T lymphocyte
NK receptor

Additional relevant MeSH terms:
Breast Neoplasms
Endometrial Neoplasms
Uterine Cervical Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Diseases
Genital Diseases, Female
Uterine Cervical Diseases

ClinicalTrials.gov processed this record on July 29, 2014